CSIMarket
 


Biora Therapeutics Inc   (BIOR)
Other Ticker:  
 

Biora Therapeutics Inc 's Working Capital Ratio

BIOR's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 0.43 below Biora Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 473 other companies have achieved higher Working Capital Ratio than Biora Therapeutics Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1868 to 4120.

Explain Working Capital Ratio
How much in Current Assets BIOR´s has?
What is the value of BIOR´s Current Liabilities?


BIOR Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 65.13 % -60.88 % -86.95 % -15.11 % -56.04 %
Y / Y Current Assets Change -58.48 % -43.66 % -50.46 % -61.28 % -50.13 %
Working Capital Ratio MRQ 0.43 2.13 6.1 1.64 1.69
BIOR's Total Ranking # 4120 # 1868 # 802 # 2616 # 2779
Seq. Current Liabilities Change 184.88 % 160.45 % -73.84 % -14.92 % -32.51 %
Seq. Current Assets Change -43.2 % -8.83 % -2.49 % -17.78 % -22.92 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 474
Healthcare Sector # 965
Overall Market # 4120


Working Capital Ratio Statistics
High Average Low
6.1 2.02 0.18
(Mar 31 2023)   (Jun 30 2014)




Financial Statements
Biora Therapeutics Inc 's Current Liabilities $ 45 Millions Visit BIOR's Balance sheet
Biora Therapeutics Inc 's Current Assets $ 19 Millions Visit BIOR's Balance sheet
Source of BIOR's Sales Visit BIOR's Sales by Geography


Cumulative Biora Therapeutics Inc 's Working Capital Ratio

BIOR's Working Capital Ratio for the trailling 12 Months

BIOR Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 65.13 % -60.88 % -86.95 % -15.11 % -56.04 %
Y / Y Current Assets TTM Growth -58.48 % -43.66 % -50.46 % -61.28 % -50.13 %
Working Capital Ratio TTM 1.42 2.14 1.87 1.59 1.97
Total Ranking TTM # 3199 # 2629 # 2521 # 2870 # 2812
Seq. Current Liabilities TTM Growth 184.88 % 160.45 % -73.84 % -14.92 % -32.51 %
Seq. Current Assets TTM Growth -43.2 % -8.83 % -2.49 % -17.78 % -22.92 %


  News about Biora Therapeutics Inc Working Capital Ratio

Biora Therapeutics Excels in Reducing Net Debt and Capitalizes on Legacy Asset Monetization for Financial Growth.

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
In a significant development, Biora Therapeutics Inc, a leading pharmaceutical company, has successfully generated $3 million in nondilutive capital through the monetization of a legacy asset. Additionally, the company has exchanged notes resulting in a further $2.8 million in capital, effectively reducing their net debt. These strategic moves come as Biora Therapeutics aims to enhance its financial stability while positioning itself for future growth and continued success in the pharmaceutical industry.
The decision to monetize a legacy asset is a clever financial move by Biora Therapeutics, enabling them to unlock hidden value and generate substantial capital without diluting their existing shares. This infusion of $3 million in nondilutive capital will undoubtedly bolster their financial resources, allowing them to pursue various growth opportunities, invest in research and development, and further strengthen their position in the pharmaceutical market.


On the trailing twelve months basis Due to in Current Liabilities in the III Quarter 2023 to $45.23 millions, cumulative Working Capital Ratio decreased to 1.42 above the BIOR average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 500 other companies have achieved higher Working Capital Ratio than Biora Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 3747, from total ranking during the twelve months ending second quarter 2023 at 4088.

Explain Working Capital Ratio
How much in Current Assets BIOR´s has?
What is the value of BIOR´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 501
Healthcare Sector # 1042
Within the Market # 4120


trailing twelve months Working Capital Ratio Statistics
High Average Low
1.59 1.27 0.2
(Dec 31 2022)   (Jun 30 2014)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Veru Inc   1.16 $ 23.506  Millions$ 20.279  Millions
Collegium Pharmaceutical Inc   1.16 $ 537.086  Millions$ 464.612  Millions
Novartis Ag  1.16 $ 30,481.000  Millions$ 26,390.000  Millions
Skye Bioscience Inc   1.11 $ 15.286  Millions$ 13.719  Millions
Ibio inc   1.11 $ 23.022  Millions$ 20.708  Millions
Ptc Therapeutics inc   1.10 $ 540.362  Millions$ 492.118  Millions
Emergent Biosolutions Inc   1.09 $ 720.800  Millions$ 664.000  Millions
Aytu Biopharma Inc   1.08 $ 70.599  Millions$ 65.463  Millions
Protokinetix Incorporated  1.07 $ 0.013  Millions$ 0.013  Millions
Molecular Templates inc   1.06 $ 22.700  Millions$ 21.512  Millions
Nascent Biotech Inc  1.05 $ 1.043  Millions$ 0.995  Millions
Kineta Inc   1.03 $ 7.843  Millions$ 7.615  Millions
Fortress Biotech Inc   1.00 $ 97.826  Millions$ 97.351  Millions
Teva Pharmaceutical Industries Limited  1.00 $ 11,425.000  Millions$ 11,394.000  Millions
Corbus Pharmaceuticals Holdings Inc   0.99 $ 31.206  Millions$ 31.542  Millions
Paxmedica Inc   0.99 $ 3.234  Millions$ 3.271  Millions
Nighthawk Biosciences inc   0.99 $ 24.180  Millions$ 24.488  Millions
Vtv Therapeutics Inc   0.99 $ 10.125  Millions$ 10.275  Millions
Journey Medical Corporation  0.98 $ 44.686  Millions$ 45.413  Millions
Reviva Pharmaceuticals Holdings Inc   0.98 $ 5.387  Millions$ 5.501  Millions
Aravive Inc   0.98 $ 9.562  Millions$ 9.777  Millions
Mustang Bio inc   0.96 $ 13.588  Millions$ 14.166  Millions
Abbvie inc   0.96 $ 33,224.000  Millions$ 34,773.000  Millions
Maravai Lifesciences Holdings Inc   0.94 $ 700.865  Millions$ 745.107  Millions
Comera Life Sciences Holdings Inc   0.91 $ 2.674  Millions$ 2.932  Millions
Earth Science Tech Inc   0.91 $ 0.462  Millions$ 0.509  Millions
Ironwood Pharmaceuticals inc   0.90 $ 253.610  Millions$ 280.579  Millions
Sonnet Biotherapeutics Holdings Inc   0.86 $ 4.738  Millions$ 5.525  Millions
Dar Bioscience Inc   0.85 $ 22.435  Millions$ 26.343  Millions
Intelgenx Technologies Corp   0.84 $ 3.211  Millions$ 3.816  Millions

Date modified: 2023-11-14T21:49:27+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com